Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials is a research paper published in UNC Libraries (2024). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 1UG1CA233373-01
UNC Lead Academic Participating Site
National Institutes of Health
Grant: 3U10CA180821-02S2
Alliance for Clinical Trials in Oncology Operations Center
National Institutes of Health
Grant: 3U24CA196171-04S1
THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCE
National Institutes of Health
Grant: 1R01CA229409-01A1
Optimizing HER2-targeting using RNA- and DNA-based predictive algorithms
National Institutes of Health
Grant: 3UG1CA233337-06S1
Yale Cancer Center NCTN LAPS
National Institutes of Health
Grant: 5U10CA180882-02
Statistics and Data Center for the Alliance for Clinical Trials in Oncology
National Institutes of Health
Grant: 5UG1CA233180-02
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
FWCI
0.00
Citation Percentile
0.1%
Fields of Study
Keywords
Sustainable Development Goals